Viridian Therapeutics announced trial results of its intravenously delivered treatment for chronic thyroid eye disease (TED), showing patients experienced...

A novel synthetic peptide with anti-inflammatory properties potentially suited to DED management is the subject of a phase 2 clinical trial.

Inflammation plays a key role in triggering and propagating dry eye disease (DED) via the ‘vicious circle’1. In severe cases, topical anti-inflammatory...

Māori are a third more likely to be admitted to hospital with injuries resulting from healthcare and are 43% more likely to be admitted because of healthcare...

US researchers found mice living in a drying atmosphere had healthier and more intact corneal surfaces when given the oral probiotic Limosilactobacillus...

An Irish design graduate has developed a wearable device to reduce distracting visual stimuli for people with attention deficit hyperactivity disorder...

A new report from the International Labour Organization (ILO) and the International Agency for the Prevention of Blindness (IAPB) is calling for better...

Okyo Pharma has announced plans to begin a phase 2 trial of OK-101, a non-opioid analgesic developed to reduce neuropathic corneal pain (NCP).

After successfully navigating Auckland’s extended Covid lockdown in 2021, the Ocular Surface Laboratory (OSL) team was excited to begin its long-awaited...

Swimmers around New South Wales‘ coast and Israel’s Sea of Galilee are being warned of a high risk of ocular infections due to elevated levels of different...

A new report from Deloitte Access Economics highlights the need to address the critical supply and distribution of optometrists throughout Aotearoa to...

The American Optometric Association (AOA) has launched Blink Land, a single-player mobile game that teaches players about eye health and its relation to...